重组人血管内皮抑制素对裸鼠骨肉瘤的抑瘤作用

目的 研究Rh-Endostatin对人骨肉瘤细胞裸鼠移植瘤的抑瘤作用.方法 建立人骨肉瘤细胞OS-732皮下移植瘤裸鼠动物模型,分为4组,分别给予(a)生理盐水;(b、c、d) Rh-Endostatin低、中和高剂量,分别为2.5、5.0和10mg/kg;为腹腔注射给药,1次/天,4周后裸鼠全部处死,称量肿瘤重量计算抑瘤率,用药疗效.对肿瘤标本进行微血管密度计数和细胞凋亡指数检测.结果 Rh-Endostatin单药2.5、5和10mg/kg治疗抑瘤率分别为25.3%、34.1%和35.7%;微血管密度:所有治疗组与对照组比较,差异均具有统计学意义(P＜0.01).凋亡指数:治疗组与对照组比较,差异均具有统计学意义(P＜0.01).结论 Rh-Endostatin单药对骨肉瘤具有明显的抑瘤作用,抗血管生成治疗骨肉瘤具有潜在的临床应用价值,值得进一步临床试验评估其疗效.

The anti-tumor effect of Rh-Endostatin against osteosarcoma in nude mice

Objective To evaluate the anti-tumor effect of Rh-Endostatin against osteosarcoma in nude mice. Methods Nude mice were subcutaneously transplanted with OS-732 human osteosarcoma. Then they were divided into 4 groups, and received varying doses of Rh-Endostatin. For the dose-response experiments, they were treated with the following agents at the indicated doses： group A with Saline （20mg/kg, once/day）, group B with Rh-Endostatin （2.5mg/ kg, once/day）, group C with Rh-Endostatin （5mg/kg, once/day）, and group D with Rh-Endostatin （10mg/kg, once/day）. Rh-Endostatin was injected through abdominal cavity. All the 4 groups were sacrificed 4 weeks after the injection. Tumor weight was measured to calculate the anti-tumor rate and to evaluate the medication efficacy. The micro-vessel density （MVD） and apoptotic index （AI） of the tumor were detected. Results For anti-tumor rate of Rh-Endostatin injection, group B reported 25.3%, group C 34.1%, and group D 35.7%. With respect to both MVD and AI, all the treatment groups （group B, group C, and group D） showed significant difference compared with the control group A （P〈0.01）. Conelusions Rh-Endostatin has significant anti-tumor effect against osteosarcoma. Antiangiogenesis in the treatment of osteosarcoma has potential clinical significance for application, and further clinical trials are needed to evaluate the efficacy.